The dosage of Lantus ® must be individualized based on clinical response frequent monitoring of blood glucose essential. Its slow release and 24-hour duration closely resemble the physiologic constant secretion of endogenous basal insulin that is typically present in patients without diabetes.
It is administered once daily, subcutaneously at the same time every day. Now that we’ve reviewed the Important Safety Information, I’d like to share a brief description of Lantus ®. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen otherwise they may not get the correct amount of insulin, which may affect their blood glucose. Lantus ® SoloSTAR ® is a disposable prefilled insulin pen. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).Īdverse reactions commonly associated with Lantus ® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.Ĭertain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. These patients should be observed for signs and symptoms of heart failure. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.įluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Discontinue Lantus ®, monitor and treat if indicated.Ī reduction in the Lantus ® dose may be required in patients with renal or hepatic impairment.Īs with all insulins, Lantus ® use can lead to life-threatening hypokalemia. Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Patients should be instructed to always verify the insulin label before each injection. Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus ®, and may be life-threatening. Do not administer Lantus ® via an insulin pump or intravenously because severe hypoglycemia can occur. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.ĭo not dilute or mix Lantus ® with any other insulin or solution. Modify insulin regimen cautiously and only under medical supervision. Monitor blood glucose in all patients treated with insulin. Insulin pens, needles, or syringes must never be shared between patients. Lantus ® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or one of its excipients. Important Limitations of Use: Lantus ® is not recommended for the treatment of diabetic ketoacidosis. Lantus ® should be administered once a day at the same time every day. Lantus ® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. This video will provide you with some basic information about Lantus ® and teach you the proper technique for injecting Lantus ® with the Lantus ® SoloSTAR ® pen.īut before we begin, let’s review some important safety information for Lantus ®. My name is Sandy, and I’d like to welcome you to the Guide to Administering Lantus ® Using the Lantus ® SoloSTAR ® Pen demonstration video.